ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial

Study limitation reported by the research below: “MASH diagnosis was 'presumed' rather than biopsy-confirmed, which is a material caveat for interpreting baseline fibrosis stage data.”